trial · primary record
Orelabrutinib
Relapsed/Refractory Marginal Zone Lymphoma (MZL)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 292 |
| Primary completion | 2032-01 |
| Primary endpoint | Complete Response Rate (CRR) assessed by Independent Review Committee (IRC) |
| Registry ID | NCT07896590 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:58.706Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07896590
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.